A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer (NCT07325136)
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Who can join: Review the eligibility criteria below.
Location: Karmanos Cancer Institute — Detroit, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Karmanos Cancer Institute — Detroit, Michigan
- Local Institution - 0026 — Buffalo, New York
- Duke Cancer Institute — Durham, North Carolina
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- SCRI Oncology Partners — Nashville, Tennessee
- Local Institution - 0029 — Beijing, Beijing Municipality
- Local Institution - 0028 — Shanghai Shi, Shanghai Municipality
- Istituto Clinico Humanitas — Rozzano, Milano
- Local Institution - 0020 — Hirakata, Osaka
- Local Institution - 0018 — Chuo-ku, Tokyo
- Oncohelp Medical Center — Timișoara, Timiș County
- Centrul de Oncologie Sf. Nectarie SRL — Craiova,
- Hospital Universitario 12 de Octubre — Madrid,
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed/Refractory Small Cell Lung Cancer
- A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) — Birmingham, Alabama
Explore by condition: All Relapsed/Refractory Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.